---
title: "BBIO.US (BBIO.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BBIO.US/news.md"
symbol: "BBIO.US"
name: "BBIO.US"
parent: "https://longbridge.com/en/quote/BBIO.US.md"
datetime: "2026-05-20T04:39:28.702Z"
locales:
  - [en](https://longbridge.com/en/quote/BBIO.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BBIO.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BBIO.US/news.md)
---

# BBIO.US (BBIO.US) — Related News

### [BridgeBio Pharma (BBIO) Gets a Hold from Citi](https://longbridge.com/en/news/286980481.md)
*2026-05-19T23:15:14.000Z*
> BridgeBio Pharma received a Hold rating and price target from Citi analyst today.Claim 55% Off TipRanksUnlock hedge fund

### [VIRGINIA RETIREMENT SYSTEMS ET Al Increases Stock Holdings in BridgeBio Pharma, Inc. $BBIO](https://longbridge.com/en/news/286643939.md)
*2026-05-16T11:19:18.000Z*
> VIRGINIA RETIREMENT SYSTEMS ET Al increased its stake in BridgeBio Pharma, Inc. by 146.2% in Q4, owning 25,850 shares va

### [BridgeBio helps spotlight ATTR-CM's hidden impact on women](https://longbridge.com/en/news/286571552.md)
*2026-05-15T13:10:28.000Z*
> BridgeBio Pharma is collaborating with BlackDoctor and HealthyWomen to raise awareness about ATTR-cardiac amyloidosis (A

### [BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches](https://longbridge.com/en/news/286199057.md)
*2026-05-13T05:04:31.000Z*
> BridgeBio Pharma executives expressed confidence in the commercial trajectory of their product Attruby during a BofA hea

### [BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1](https://longbridge.com/en/news/286092733.md)
*2026-05-12T11:31:23.000Z*
> The primary findings of Phase 3 CALIBRATE were recently revealed during a presentation at the 2026 ECE. The results show

### [BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial](https://longbridge.com/en/news/286086171.md)
*2026-05-12T10:39:45.000Z*
> A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings.

### [Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure | BBIO Stock News](https://longbridge.com/en/news/285952654.md)
*2026-05-11T05:30:36.000Z*
> Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worse